Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) has been one of the top performing stocks of 2012. Not just in emerging pharma and in biotech, but across the board. Now we have some more good news of an orphan drug designation being granted out of Europe.
The European Commission has granted an Orphan Drug Designation for the company’s TH-302, a hypoxia-targeted drug for the treatment of soft tissue sarcoma. Soft tissue sarcoma is an aggressive form of cancer for which there is a significant unmet medical need.
The company noted that TH-302 was designed “to selectively target hypoxic regions within tumors, which are believed to not be effectively treated with current therapy.”
Keep in mind that Threshold shares were well under $2.00 at the start of 2012. Shares closed on Thursday at $6.73. This stock has traded in a range of $1.18 to $7.50 over the last year and its market capitalization rate is $330 million.
JON C. OGG
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
